Worked to the bone: antibody-based conditioning as the future of transplant biology
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Worked to the bone: antibody-based conditioning as the future of transplant biology
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-19
DOI
10.1186/s13045-022-01284-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
- (2021) Beatriz G. de la Torre et al. MOLECULES
- Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
- (2021) Cécile Pautas et al. BONE MARROW TRANSPLANTATION
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
- (2021) Agnieszka Tomaszewska et al. Frontiers in Immunology
- Obesity-induced inflammation: The impact of the hematopoietic stem cell niche
- (2021) Emily Bowers et al. JCI Insight
- Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
- (2021) Zheng Tian et al. Journal of Hematology & Oncology
- CAR-T cell therapy: current limitations and potential strategies
- (2021) Robert C. Sterner et al. Blood Cancer Journal
- Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII
- (2021) Athena L. Russell et al. Molecular Therapy-Methods & Clinical Development
- A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key
- (2021) Asmaa Ferdjallah et al. Frontiers in Pediatrics
- The Hematopoietic Bone Marrow Niche Ecosystem
- (2021) Julia Fröbel et al. Frontiers in Cell and Developmental Biology
- A Bispecific Antibody Targeting CD117 and CD3 Enables T Cell Mediated Killing of CD117-Expressing Healthy and Malignant Hematopoietic Cells
- (2021) Jonathan D Kiefer et al. BLOOD
- A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo
- (2021) Lucas C M Arruda et al. BLOOD
- Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency
- (2020) Rajni Agarwal et al. BLOOD
- A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates
- (2020) John F. Tisdale et al. BLOOD
- Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
- (2020) Alexandros Spyridonidis et al. BONE MARROW TRANSPLANTATION
- Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation
- (2020) Deepa Jagadeesh et al. CANCER
- Effective multi-lineage engraftment in a mouse model of Fanconi anemia using non-genotoxic antibody-based conditioning
- (2020) Meera A. Srikanthan et al. Molecular Therapy-Methods & Clinical Development
- 90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma
- (2020) Kevin C. Conlon et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Efficacy and safety of anti-CD45-Saporin as conditioning agent for RAG deficiency
- (2020) Maria Carmina Castiello et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells
- (2020) Renier Myburgh et al. LEUKEMIA
- 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
- (2020) Matteo Libero Baroni et al. Journal for ImmunoTherapy of Cancer
- Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma
- (2020) Sherilyn A. Tuazon et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions
- (2020) Claire Burney et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Overhauling CAR T Cells to Improve Efficacy, Safety and Cost
- (2020) Leonardo Chicaybam et al. Cancers
- Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice
- (2019) Hye-Sook Kwon et al. BLOOD
- Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation
- (2019) Agnieszka Czechowicz et al. Nature Communications
- Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation
- (2019) Zhanzhuo Li et al. Nature Communications
- Haematopoietic stem cell activity and interactions with the niche
- (2019) Sandra Pinho et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice
- (2019) Wendy W. Pang et al. BLOOD
- Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
- (2019) Mazyar Shadman et al. BONE MARROW TRANSPLANTATION
- Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance
- (2019) Benson M. George et al. Cell Stem Cell
- An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
- (2019) Kristopher D Marjon et al. BLOOD
- Immunophenotypic- and Molecular Analysis of Human Hematopoietic Stem and Progenitor Heterogeneity
- (2019) Mikael Sommarin et al. BLOOD
- Characteristics of graft‐ versus ‐host disease occurring after alemtuzumab‐containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival
- (2019) Maria C. Finazzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
- (2019) Phuong Vo et al. HAEMATOLOGICA
- Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience
- (2018) Mary A. Slatter et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-Term Follow-Up of 90 Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma
- (2018) Camille E. Puronen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables
- (2018) J. Tay et al. BONE MARROW TRANSPLANTATION
- Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review
- (2018) Adrien Paix et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Niches for Hematopoietic Stem Cells and Their Progeny
- (2018) Qiaozhi Wei et al. IMMUNITY
- Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment
- (2018) Yasuyuki Arai et al. MOLECULAR THERAPY
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward
- (2018) Jessica T. Leonard et al. Current Hematologic Malignancy Reports
- Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease
- (2018) Ying-Jun Chang et al. Frontiers in Immunology
- The immunological function of CD52 and its targeting in organ transplantation
- (2017) Yang Zhao et al. INFLAMMATION RESEARCH
- Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma
- (2017) Narendranath Epperla et al. Journal of Hematology & Oncology
- Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis
- (2017) Aurélie Hérault et al. NATURE
- Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies
- (2016) Vanessa E. Kennedy et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network
- (2016) Ginna G. Laport et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin
- (2016) Rahul Palchaudhuri et al. NATURE BIOTECHNOLOGY
- Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy
- (2016) Akanksha Chhabra et al. Science Translational Medicine
- Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant
- (2016) Bernard L Marini et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Long-Term Outcomes of Patients with Persistent Indolent B Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation
- (2015) Ryan D. Cassaday et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT
- (2015) X Cahu et al. BONE MARROW TRANSPLANTATION
- Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era
- (2015) A Mussetti et al. BONE MARROW TRANSPLANTATION
- New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients*
- (2015) Matt S. Zinter et al. CRITICAL CARE MEDICINE
- Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma
- (2015) Martin D. Berger et al. HEMATOLOGICAL ONCOLOGY
- Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group
- (2015) H. Quach et al. INTERNAL MEDICINE JOURNAL
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
- (2015) Eva Havrdova et al. Therapeutic Advances in Neurological Disorders
- One million haemopoietic stem-cell transplants: a retrospective observational study
- (2015) Alois Gratwohl et al. Lancet Haematology
- Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen
- (2014) Matthew Mei et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
- (2014) B. Gyurkocza et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Vedolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies
- (2014) Craig S. Sauter et al. LEUKEMIA & LYMPHOMA
- Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
- (2013) Ayman Saad et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- "Designed" grafts for HLA-haploidentical stem cell transplantation
- (2013) M. F. Martelli et al. BLOOD
- Haematopoietic stem cell niches: new insights inspire new questions
- (2013) Fernando Ugarte et al. EMBO JOURNAL
- Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution
- (2012) Jason Law et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
- (2012) Avichai Shimoni et al. CANCER
- A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen
- (2011) Prakash Satwani et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation–Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma
- (2011) Amrita Krishnan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases
- (2011) A. S. Schulz et al. BLOOD
- 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma
- (2011) A. K. Gopal et al. BLOOD
- Further phenotypic characterization of the primitive lineage− CD34+CD38−CD90+CD45RA− hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia
- (2011) D Wisniewski et al. Blood Cancer Journal
- A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents
- (2010) J Styczynski et al. BONE MARROW TRANSPLANTATION
- CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?
- (2010) Cindy Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma
- (2010) Karban Josef et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects
- (2010) Myriam N Bouchlaka et al. Immunotherapy
- The safety and side effects of monoclonal antibodies
- (2010) Trevor T. Hansel et al. NATURE REVIEWS DRUG DISCOVERY
- Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation
- (2010) Ben Carpenter et al. TRANSPLANTATION
- Defining the Intensity of Conditioning Regimens: Working Definitions
- (2009) Andrea Bacigalupo et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML
- (2008) R K Malladi et al. BONE MARROW TRANSPLANTATION
- Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia
- (2008) M. Bornhauser et al. CLINICAL CANCER RESEARCH
- CD25 as an immune regulatory molecule expressed on myeloid dendritic cells
- (2008) Julia Driesen et al. IMMUNOBIOLOGY
- CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules
- (2008) Shoham Shivtiel et al. JOURNAL OF EXPERIMENTAL MEDICINE
- FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Demko et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started